RO7033877 lung penetration in healthy volunteers

Phase 1, open-label, single-arm trial of murepavadin in Pseudomonas aeruginosa infection and bacterial pneumonia, sponsored by Roche. Primary endpoints: Multiple-dose pharmacokinetics of RO7033877 for plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM): Cmax and AUC at 5 days and ELF and AM/Plasma Ratios of Cmax and AUC at 5 days. Started Jun 2014; status: completed.